Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. (Q36543063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Guillermo Keller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Valeria Beruto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Silvina Santoro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Guillermo Di Girolamo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

887-895

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16859392%20AND%20SRC:MED&resulttype=core&format=json

Incretin mimetics as emerging treatments for type 2 diabetes

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Glucagon-like peptide 1(GLP-1) in biology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Standards of medical care in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.887